e-learning
resources
Virtual 2020
Pre-Congress Content
Pathophysiology of pulmonary hypertension
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Regulation of Type I cytokine receptors as a target for pulmonary arterial hypertension treatment?
E. Jutant (Le Kremlin-Bicêtre, France), L. Tu (Le Kremlin-Bicêtre, France), B. Le Vely (Le Kremlin-Bicêtre, France), R. Thuillet (Le Kremlin-Bicêtre, France), M. Humbert (Le Kremlin-Bicêtre, France), C. Guignabert (Le Kremlin-Bicêtre, France), A. Huertas (Le Kremlin-Bicêtre, France)
Source:
Virtual Congress 2020 – Pathophysiology of pulmonary hypertension
Session:
Pathophysiology of pulmonary hypertension
Session type:
E-poster session
Number:
3557
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
E. Jutant (Le Kremlin-Bicêtre, France), L. Tu (Le Kremlin-Bicêtre, France), B. Le Vely (Le Kremlin-Bicêtre, France), R. Thuillet (Le Kremlin-Bicêtre, France), M. Humbert (Le Kremlin-Bicêtre, France), C. Guignabert (Le Kremlin-Bicêtre, France), A. Huertas (Le Kremlin-Bicêtre, France). Regulation of Type I cytokine receptors as a target for pulmonary arterial hypertension treatment?. 3557
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The definition of pulmonary hypertension: history, practical implications and current controversies
Should we screen for hereditary pulmonary hypertension?
Patient with ankylosing spondylitis and pulmonary hypertension
Related content which might interest you:
Decreased expression of the TGF-beta type I receptor ALK1 in pulmonary arterial hypertension
Source: Annual Congress 2007 - Cellular and molecular aspects of pulmonary hypertension
Year: 2007
Olfactory receptors in pulmonary arterial hypertension: A novel pathway of vascular remodeling?
Source: International Congress 2015 – Pulmonary hypertension: novel insights into the biology of the disease
Year: 2015
Leptin signalling system as a target for pulmonary arterial hypertension therapy
Source: Eur Respir J 2015; 45: 1066-1080
Year: 2015
Current medical therapies in pulmonary arterial hypertension
Source: Eur Respir Mon 2012; 57: 26-41
Year: 2012
Pulmonary arterial hypertension associated with fenfluramine exposure: report of 109 cases
Source: Eur Respir J 2008; 31: 343-348
Year: 2008
Roundabout (Robo) receptors on pulmonary artery endothelial cells: Implications for pulmonary arterial hypertension
Source: International Congress 2016 – The nature of pulmonary hypertension
Year: 2016
NMDA receptor crosstalk with PDGFR-β and BMPR2 is involved in smooth muscle cell proliferation in pulmonary arterial hypertension
Source: International Congress 2016 – The nature of pulmonary hypertension
Year: 2016
Inhibiting oestrogen signalling in pulmonary arterial hypertension: sex, drugs and research
Source: Eur Respir J, 50 (2) 1700983; 10.1183/13993003.00983-2017
Year: 2017
IL-6 receptor overexpression in pulmonary arterial smooth muscle cells in idiopathic pulmonary hypertension
Source: International Congress 2015 – Pulmonary hypertension: novel insights into the biology of the disease
Year: 2015
MIF/CD74 contributes to the endothelial pro-inflammatory phenotype in pulmonary arterial hypertension
Source: Annual Congress 2013 –Pulmonary circulation: basic science
Year: 2013
Endothelin receptor expression in idiopathic pulmonary arterial hypertension: effect of bosentan and epoprostenol treatment
Source: Eur Respir J 2011; 38: 851-860
Year: 2011
Targeting BMPR-II in pulmonary arterial hypertension
Source: International Congress 2016 – Pulmonary arterial hypertension: future therapeutic approaches
Year: 2016
Treatment of early systemic sclerosis associated pulmonary arterial hypertension with endothelin receptor antagonists improves survival
Source: Annual Congress 2007 - Clinical aspects of pulmonary arterial hypertension
Year: 2007
Inflammatory mediators contribute to pulmonary arterial cell dysfunction in a pulmonary arterial hypertension patient with
BMPR2
mutation
Source: Annual Congress 2013 –Pulmonary circulation: clinical pulmonary hypertension I
Year: 2013
Involvement of CFTR in the pathogenesis of pulmonary arterial hypertension
Source: Eur Respir J, 58 (5) 2000653; 10.1183/13993003.00653-2020
Year: 2021
Activation of AMPK inhibits pulmonary arterial remodeling
Source: International Congress 2015 – Pulmonary hypertension: novel insights into the biology of the disease
Year: 2015
Nuclear IL-33 arguments ST2 receptor expression in pulmonary arterial endothelial cells: Implication in the pathogenesis and progression of pulmonary arterial hypertension
Source: International Congress 2014 – Pulmonary hypertension: pathobiology
Year: 2014
Stabilised ferroportin activity affects pulmonary vascular cells responses: implications for pulmonary hypertension
Source: International Congress 2018 – Experimental research in pulmonary hypertension
Year: 2018
RESPITE: Riociguat in pulmonary arterial hypertension patients with an inadequate response to phosphodiesterase type 5 inhibitors
Source: International Congress 2016 – Clinic of pulmonary hypertension
Year: 2016
Is there a role for endothelin-1 receptor antagonists in the treatment of lung fibrosis associated with pulmonary hypertension?
Source: Eur Respir J, 52 (2) 1801287; 10.1183/13993003.01287-2018
Year: 2018
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept